AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20169950 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.5 mg x kg(‐1)
Number of subjects: 30
Study 20169950 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg x kg(‐1)
Number of subjects: 30
Study 18987368 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg of testosterone per day
Number of subjects: 814
Study 18987368 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg of testosterone per day
Number of subjects: 814
Study 18987368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 814
Study 15694877 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic daily diary assessment of pain-related variables
Number of subjects: 71
Study 12752557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric hyperoxia (HBO) exposure for O2 divers (6 hours, PiO2 varied from 1.15 to 2.7 ATA)
Number of subjects: 17
Study 12752557 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric hyperoxia (HBO) exposure for air divers (2 hours, PiO2 constant at 1.15 ATA)
Number of subjects: 17
Study 10586979 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling and home glucose monitoring (HBGM)
Number of subjects: 83
Study 10586979 — intervention group
Group type: COMPARATOR
Intervention: Standard euglycemic diet and home glucose monitoring (HBGM)
Number of subjects: 83
Study 8901368 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale without hashmarks
Number of subjects: 213
Study 8901368 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale with hashmarks
Number of subjects: 213
Study 8901368 — intervention group
Group type: COMPARATOR
Intervention: Descriptive terms ('mildly', 'moderately', 'severely')
Number of subjects: 213
Study 8901368 — intervention group
Group type: EXPERIMENTAL
Intervention: Errors of order
Number of subjects: 213
Study 8901368 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive terms with numerical values
Number of subjects: 213
Study 1876742 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 0.05 mg of fentanyl
Number of subjects: 204
Study 1876742 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine alone
Number of subjects: 204
Study 7048881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 62
Study 7048881 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 62
Study 31518627 — intervention group
Group type: COMPARATOR
Intervention: Gender (Women)
Number of subjects: 3213
Study 31518627 — intervention group
Group type: COMPARATOR
Intervention: Presence of a walking path
Number of subjects: 3213
Study 28177715 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-S
Number of subjects: 25
Study 28177715 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-F
Number of subjects: 25
Study 28177715 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 25
Study 25199441 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical-touch fitting approach
Number of subjects: 31
Study 25199441 — intervention group
Group type: COMPARATOR
Intervention: Three-point-touch fitting approach
Number of subjects: 31
Study 25199441 — intervention group
Group type: COMPARATOR
Intervention: Both fitting approaches
Number of subjects: 31
Study 24060194 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-enhanced CBT
Number of subjects: 50
Study 24060194 — intervention group
Group type: COMPARATOR
Intervention: Individual CBT
Number of subjects: 50
Study 21532072 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic implementation of behavioral interventions including trauma-informed care training, changes to unit rules and language, changes to the physical characteristics of the therapeutic environment, and involvement of patients in treatment planning.
Number of subjects: 89783
Study 21532072 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes to the physical environment during the intervention rollout period.
Number of subjects: 89783
Study 18971549 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (12.5 mg/d)
Number of subjects: 18
Study 18971549 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 18
Study 18971549 — intervention group
Group type: COMPARATOR
Intervention: Control (antiplatelet agents)
Number of subjects: 18
Study 16155076 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 8 mg daily for 12 weeks
Number of subjects: 42
Study 16155076 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 2 mg daily for 12 weeks
Number of subjects: 42
Study 16155076 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg daily for 12 weeks
Number of subjects: 42
Study 16155076 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 42
Study 14640835 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarized with repetitions of 2 words and tested on orientation times to 4 passages (2 familiarized words)
Number of subjects: 0
Study 10849267 — intervention group
Group type: COMPARATOR
Intervention: Interferon-a2a (IFN) alone
Number of subjects: 40
Study 10849267 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Interferon-a2a (IFN) with oral ganciclovir
Number of subjects: 40
Study 9089855 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms/mL with lidocaine 1.5%
Number of subjects: 40
Study 9089855 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine 5 micrograms/mL with lidocaine 1.5%
Number of subjects: 40
Study 8260124 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 12
Study 8260124 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 12
Study 8260124 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate 60 mg
Number of subjects: 12
Study 8260124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2994451 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 10
Study 2994451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30600521 — intervention group
Group type: EXPERIMENTAL
Intervention: Thula Baba Box (TBB) and monthly Community Health Worker (CHW) visits
Number of subjects: 72
Study 30600521 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice (Control)
Number of subjects: 72
Study 29970875 — intervention group
Group type: EXPERIMENTAL
Intervention: Breviscapine (40 mg)
Number of subjects: 78
Study 29970875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 28708702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic (IH) protocol (n = 11)
Number of subjects: 19
Study 28708702 — intervention group
Group type: COMPARATOR
Intervention: Control group (normoxia; n = 8)
Number of subjects: 19
Study 26307245 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered model of care
Number of subjects: 131
Study 26307245 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers and enablers for the person-centered model
Number of subjects: 131
Study 24274215 — intervention group
Group type: EXPERIMENTAL
Intervention: Blakesley forceps
Number of subjects: 311
Study 24274215 — intervention group
Group type: COMPARATOR
Intervention: Microdebrider
Number of subjects: 311
Study 21950300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Methotrexate (MTX) 2.5 mg daily for 4 weeks
Number of subjects: 101
Study 21950300 — intervention group
Group type: COMPARATOR
Intervention: Oral Methotrexate (MTX) weekly (not specified dosage)
Number of subjects: 101
Study 21950300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Methotrexate (MTX) daily
Number of subjects: 101
Study 21950300 — intervention group
Group type: COMPARATOR
Intervention: Oral Methotrexate (MTX) weekly
Number of subjects: 101
Study 18449064 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% chlorhexidine solution
Number of subjects: 286
Study 18449064 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50% chlorhexidine solution
Number of subjects: 286
Study 18449064 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.00% chlorhexidine solution
Number of subjects: 286
Study 18449064 — intervention group
Group type: COMPARATOR
Intervention: Control (no chlorhexidine)
Number of subjects: 286
Study 18449064 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel prick blood sample
Number of subjects: 286
Study 16540246 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate antipsychotic treatment
Number of subjects: 114
Study 16540246 — intervention group
Group type: COMPARATOR
Intervention: Control groups (healthy controls, cannabis controls, multiple substance controls)
Number of subjects: 114
Study 12488289 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 6 mg subcutaneous injection of pegfilgrastim
Number of subjects: 157
Study 12488289 — intervention group
Group type: COMPARATOR
Intervention: Daily 5 mg/kg subcutaneous injections of filgrastim
Number of subjects: 157
Study 11403727 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 100 mg/day
Number of subjects: 519
Study 11403727 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg/day
Number of subjects: 519
Study 11403727 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg/day
Number of subjects: 519
Study 11403727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study 11403727 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 519
Study 9517526 — intervention group
Group type: EXPERIMENTAL
Intervention: rice ORS containing 50 g/l rice and 70 mmol/l Na+
Number of subjects: 123
Study 9517526 — intervention group
Group type: COMPARATOR
Intervention: WHO ORS
Number of subjects: 123
Study 9517526 — intervention group
Group type: COMPARATOR
Intervention: ORS containing 70 mmol/l Na+ and 16.2 g/l glucose
Number of subjects: 123
Study 9517526 — intervention group
Group type: COMPARATOR
Intervention: rice ORS containing 50 g/l rice and 90 mmol/l Na+
Number of subjects: 123
Study 8277035 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tretinoin cream
Number of subjects: 45
Study 8277035 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 45
Study 3140683 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate (10 mg/kg x 3 doses)
Number of subjects: 2628
Study 3140683 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel (40 mg/kg x 1 dose)
Number of subjects: 2628
Study 3140683 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate
Number of subjects: 2628
Study 3140683 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 2628
Study 3140683 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate and Praziquantel
Number of subjects: 2628
Study 29059371 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple arterial grafts
Number of subjects: 4300
Study 29059371 — intervention group
Group type: COMPARATOR
Intervention: Single arterial graft (SAG)
Number of subjects: 4300
Study 26058718 — intervention group
Group type: EXPERIMENTAL
Intervention: Transapical transcatheter aortic valve replacement (TA‐TAVR)
Number of subjects: 875
Study 26058718 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 875
Study 23883816 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic bioabsorbable antibiotic-soaked nasal sponge in the middle meatus (MM)
Number of subjects: 321
Study 23883816 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative oral antibiotic prophylaxis (1 week) and saline-soaked bioabsorbable MM sponge
Number of subjects: 321
Study 21039936 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B at 3 mg kg(‐1) QD for 14 days, followed by 3 mg kg(‐1) QD
Number of subjects: 201
Study 21039936 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B at 10 mg kg(‐1) QD for 14 days, followed by 3 mg kg(‐1) QD
Number of subjects: 201
Study 19051066 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (5 microM)
Number of subjects: 18
Study 19051066 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 microM)
Number of subjects: 18
Study 19051066 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal octanoate oxidation
Number of subjects: 18
Study 19051066 — intervention group
Group type: COMPARATOR
Intervention: Muscle biopsy myopathy scores
Number of subjects: 18
Study 17377982 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic apheresis
Number of subjects: 0
Study 15252410 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, low-to-moderate intensity exercise and education program
Number of subjects: 32
Study 15252410 — intervention group
Group type: COMPARATOR
Intervention: Education only program
Number of subjects: 32
Study 11422662 — intervention group
Group type: EXPERIMENTAL
Intervention: Kitavan males
Number of subjects: 387
Study 11422662 — intervention group
Group type: EXPERIMENTAL
Intervention: Kitavan females
Number of subjects: 387
Study 11422662 — intervention group
Group type: COMPARATOR
Intervention: Swedish males
Number of subjects: 387
Study 11422662 — intervention group
Group type: COMPARATOR
Intervention: Swedish females
Number of subjects: 387
Study 9373044 — intervention group
Group type: EXPERIMENTAL
Intervention: AV nodal ablation and single- or dual-chamber pacemaker implantation
Number of subjects: 64
Study 7837745 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermatic index of toxicity measured using bull sperm cells in blood serum filtrate from patients with peritonitis
Number of subjects: 0
Study 7837745 — intervention group
Group type: COMPARATOR
Intervention: Control glucose-nitrate solution
Number of subjects: 0
Study 31515837 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management (SX)
Number of subjects: 98
Study 31515837 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical management (non-SX)
Number of subjects: 98
Study 27901334 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcobalamin (MC)
Number of subjects: 40
Study 27901334 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 40
Study 27901334 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (MC and ALA)
Number of subjects: 40
Study 26285161 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0
Study 26285161 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0
Study 24708696 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin infusion (CIPII)
Number of subjects: 19
Study 24708696 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (SC) therapy
Number of subjects: 19
Study 24708696 — intervention group
Group type: EXPERIMENTAL
Intervention: CIPII
Number of subjects: 19
Study 23043166 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 1030
Study 23043166 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 1030
Study 19843296 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid avoidance
Number of subjects: 197
Study 19843296 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid maintenance
Number of subjects: 197
Study 18661082 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% mepivacaine hydrochloride injection
Number of subjects: 104
Study 18661082 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with adrenaline
Number of subjects: 104
Study 16450593 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (250 microg/kg) injected into the aortic root
Number of subjects: 30
Study 16450593 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection
Number of subjects: 30
Study 12598719 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium-administered group (oral administration of lyophilized bifidobacteria, Bifidobacterium breve M‐16V strain)
Number of subjects: 15
Study 12598719 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium-administered group
Number of subjects: 15
Study 10469967 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletonized internal thoracic artery (group I, n = 11)
Number of subjects: 23
Study 10469967 — intervention group
Group type: COMPARATOR
Intervention: Pedicled internal thoracic artery (group II, n = 12)
Number of subjects: 23
Study 10469967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled left internal thoracic artery
Number of subjects: 23
Study 8693541 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg OKT3
Number of subjects: 30
Study 8693541 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg OKT3
Number of subjects: 30
Study 1657197 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of alcoholics and drug addicts
Number of subjects: 450
Study 1657197 — intervention group
Group type: COMPARATOR
Intervention: Separate treatment of alcoholics and drug addicts
Number of subjects: 450
Study 7080887 — intervention group
Group type: EXPERIMENTAL
Intervention: Active person‐to‐person recruitment
Number of subjects: 52
Study 7080887 — intervention group
Group type: COMPARATOR
Intervention: Normal school publicity procedure
Number of subjects: 52
Study 7080887 — intervention group
Group type: EXPERIMENTAL
Intervention: Active person‐to‐person recruitment (subsequent application)
Number of subjects: 52
Study 31841507 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU loading dose followed by 20,000 IU/week)
Number of subjects: 417
Study 31841507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 29030792 — intervention group
Group type: EXPERIMENTAL
Intervention: Identity Project intervention
Number of subjects: 215
Study 29030792 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 215
Study 27210845 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Thai massage (TTM)
Number of subjects: 36
Study 27210845 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 24786928 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX), etanercept, and rapidly tapered prednisolone (MEP)
Number of subjects: 85
Study 24786928 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 85
Study 24786928 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label MEP treatment
Number of subjects: 85
Study 24786928 — intervention group
Group type: EXPERIMENTAL
Intervention: MEP (more aggressive therapy)
Number of subjects: 85
Study 24786928 — intervention group
Group type: EXPERIMENTAL
Intervention: American College of Rheumatology Pediatric 70 response at 4 months
Number of subjects: 85
Study 22424948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycled parenteral nutrition (n = 34)
Number of subjects: 70
Study 22424948 — intervention group
Group type: COMPARATOR
Intervention: Continuous parenteral nutrition (n = 36)
Number of subjects: 70
Study 21061393 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% capsaicin cream
Number of subjects: 32
Study 21061393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 18930488 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy
Number of subjects: 431
Study 18930488 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 431
Study 18930488 — intervention group
Group type: COMPARATOR
Intervention: Seminal vesicle negative disease
Number of subjects: 431
Study 18930488 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminal vesicle positive disease
Number of subjects: 431
Study 15949199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cling wrap (CW)
Number of subjects: 51
Study 15949199 — intervention group
Group type: COMPARATOR
Intervention: No cling wrap (NCW)
Number of subjects: 51
Study 12078912 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cycles of chemotherapy (CT) with (sub)total nodal irradiation (RT) as consolidation treatment.
Number of subjects: 0
Study 12078912 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive therapy including intensified cytoreductive CT and high-dose CT with autologous stem-cell transplantation.
Number of subjects: 0
Study 12078912 — intervention group
Group type: EXPERIMENTAL
Intervention: Four escalated BEACOPP followed by four baseline BEACOPP.
Number of subjects: 0
Study 12078912 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of eight doxorubicin-bleomycin-vinblastine-dacarbazine.
Number of subjects: 0
Study 10422928 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg/kg
Number of subjects: 117
Study 10422928 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg
Number of subjects: 117
Study 10422928 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg/kg after 2 min
Number of subjects: 117
Study 10422928 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg after 2 min
Number of subjects: 117
Study 10422928 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg/kg after 5 min
Number of subjects: 117
Study 10422928 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg after 5 min
Number of subjects: 117
Study 10422928 — intervention group
Group type: COMPARATOR
Intervention: Control (no neostigmine)
Number of subjects: 117
Study 8524605 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNA labelling
Number of subjects: 11
Study 8524605 — intervention group
Group type: EXPERIMENTAL
Intervention: MIB‐1 labelling
Number of subjects: 11
Study 2255747 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg)
Number of subjects: 0
Study 2255747 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 6996934 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dezocine
Number of subjects: 20
Study 6996934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30169439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Applications for Life Management (CALM)
Number of subjects: 224
Study 30169439 — intervention group
Group type: COMPARATOR
Intervention: Brain Health Training (Control)
Number of subjects: 224
Study 29113731 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fexinidazole (1800 mg on days 1-4, 1200 mg on days 5-10)
Number of subjects: 394
Study 29113731 — intervention group
Group type: COMPARATOR
Intervention: Nifurtimox eflornithine combination therapy (15 mg/kg per day for 10 days, 400 mg/kg per day for 7 days)
Number of subjects: 394